You searched for baricitinib - Page 4 of 20

Abstract Number: 0224 • ACR Convergence 2020
Efficacy of Long-term Treatment with Baricitinib 2 Mg in Patients with Active Rheumatoid Arthritis
Alvin Wells¹, Bochao Jia², Li Xie², Guillermo Valenzuela³, Edward C Keystone⁴, Zhanguo Li⁵, Amanda Quebe², Kirstin Griffing², Susan Otawa² and Boulos Haraoui⁶, ¹Aurora Rheumatology and Immunotherapy Center, Franklin, ²Eli Lilly and Company, Indianapolis, IN, ³Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵Peking University People’s Hospital, Xicheng, Beijing, China (People's Republic), ⁶Institut de Rhumatologie de Montréal, Montreal, QC, Canada
Background/Purpose: The short-term efficacy of baricitinib was demonstrated previously.1,2 The objectives of this post-hoc analysis were to evaluate long-term efficacy of once-daily baricitinib 2 mg…
Abstract Number: 0453 • ACR Convergence 2020
Monitoring of BK Reactivation and Long-term Safety on JAK1/2 Inhibition with Baricitinib
Kader Cetin Gedik¹, Gema Souto Adeva², Jenna Wade¹, Gina Montealegre Sanchez³, Adriana de Jesus⁴ and Raphaela Goldbach-Mansky⁵, ¹Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, MD, ²Translational Autoinflammatory Disease Section (TADS)/NIAID/ NIH, Bethesda, ³Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Rockville, MD, ⁴Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Silver Spring, MD, ⁵Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Potomac, MD
Background/Purpose: Baricitinib has been used to treat pediatric patients (pts) with Type 1 Interferonopathies1. Safety profile including BK viral reactivation in urothelium and pharmacokinetic model…
Abstract Number: 0848 • ACR Convergence 2020
Delineation of a Proinflammatory Cytokine Profile Targeted by Janus Kinase 1/2 Inhibition Using Baricitinib in a Phase 2 Systemic Lupus Erythematosus Trial
Thomas Dörner¹, Yoshiya Tanaka², Michelle Petri³, Josef Smolen⁴, Daniel Wallace⁵, Brenda Crowe⁶, Ernst Dow⁶, Richard Higgs⁶, Guilherme Rocha⁶, Robert Benschop⁶, Maria Silk⁶, Stephanie de Bono⁶, Robert Hoffman⁶ and Damiano Fantini⁶, ¹DRFZ and Charité University Hospitals, Berlin, Germany, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, ⁵Cedars-Sinai Medical Center/UCLA, Los Angeles, CA, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Given the unmet clinical needs in systemic lupus erythematosus (SLE), including poor disease control and drug toxicities, new therapies are needed. In a phase…
Abstract Number: 1228 • ACR Convergence 2020
Baricitinib 2-mg Provides Greater Improvements in Patient-Reported Outcomes Across All Disease Activity Levels Compared to Placebo: Post-hoc Analyses of RA-BEACON and RA-BUILD Trials
Clifton Bingham III¹, Bochao Jia², Jianmin Wu², Amanda Quebe², Carol Kannowski², Susan Otawa², Yun-Fei Chen², Kirstin Griffing², Dongyi He³ and Dalton Sholter⁴, ¹Johns Hopkins University, Baltimore, MD, ²Eli Lilly and Company, Indianapolis, IN, ³Shanghai Guanghua Hospital, Shanghai, Shanghai, China (People's Republic), ⁴University of Alberta, Edmonton, AB, Canada
Background/Purpose: Baricitinib (BARI) improved patient-reported outcomes (PROs) in patients with insufficient response or intolerance to ≥1 tumor necrosis factor inhibitors (TNFi) or other biological disease-modifying…
Abstract Number: 1235 • ACR Convergence 2020
Radiographic Progression of Structural Joint Damage over 5 Years of Baricitinib Treatment in Patients with Rheumatoid Arthritis: Results from RA-BEYOND
Désirée van der Heijde¹, Cynthia E Kartman², Li Xie², Scott Beattie², Douglas Schlichting², Patrick Durez³, Yoshiya Tanaka⁴ and Roy Fleischmann⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Eli Lilly and Company, Indianapolis, IN, ³Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Baricitinib (BARI) is an oral, reversible and selective Janus kinase 1 and 2 inhibitor. Treatment with once-daily oral BARI resulted in low rates of…
Abstract Number: 1558 • ACR Convergence 2020
Cinematic Rendering Enables Depiction of Bone Anabolic Effects in Patients Treated with Baricitinib
Sara Bayat¹, David Simon², Louis Schuster², Georg Schett³ and Arnd Kleyer², ¹Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ³Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany
Background/Purpose: Preclinical studies show that tsDMARDs such as baricitinib may be a therapeutic agent for bone anabolic effects by increasing osteoblast function in inflammatory conditions.[1]…
Abstract Number: 1990 • ACR Convergence 2020
Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis
Hanna Kim¹, Lylan Bergeron², Samantha Dill², Michelle O'Brien², Laura Vian³, Minal Jain⁴, Manuk Manukyan², Xiaobai Li⁵, Shajia Lu³, Wanxia L. Tsai³, Kalyani Mishra Thakur⁶, Yinghui Shi⁶, Massimo Gadina⁷, April Brundidge², Michelle Millwood², Lisa G. Rider⁸ and Robert Colbert², ¹Juvenile Myositis Pathogenesis and Therapeutics Unit / NIAMS / National Institutes of Health, Bethesda, MD, ²Pediatric Clinical Trials Unit and Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ³Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ⁴Rehabilitation Medicine Department, Physical Therapy Section, Clinical Research Center, NIH, Bethesda, MD, ⁵Biostatistics and Clinical Epidemiology Service, Clinical Center, NIH, Bethesda, MD, ⁶Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, ⁸Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…
Abstract Number: 313 • 2019 ACR/ARP Annual Meeting
Screening and Treating Hyperlipidemia in Patient’s on Tofacitinib, Tocilizumab, Sarilumab, and Baricitinib
William Torelli¹, James Ross ², Thomas Quinn ², Kourtney Erickson ¹, Andrea Soliman ¹ and Attiya Harit ³, ¹Lehigh Valley Health Network, Allentown, PA, ²lehigh valley health network, allentown, ³lehigh valley health organization, allentown
Background/Purpose: Background/Purpose: Tofacitinib and baricitinib (JAK inhibitors) are agents used for rheumatoid arthritis (RA), seronegative spondyloarthropathy (SpA), and juvenile idiopathic arthritis (JIA). Tocilizumab and sarilumab…
Abstract Number: 390 • 2019 ACR/ARP Annual Meeting
Preliminary Response to Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis
Hanna Kim¹, Samantha Dill ², Michelle O'Brien ², Minal Jain ³, Shajia Lu ⁴, Wanxia Tsai ⁴, Yinghui Shi ⁵, Laura Vian ⁴, Massimo Gadina ⁴, Michelle Millwood ², April Brundidge ², Lisa G. Rider ⁶ and Robert Colbert ¹, ¹Pediatric Clinical Trials Unit, Pediatric Translational Research Branch, NIAMS, NIH, Bethesda, MD, ²Pediatric Clinical Trials Unit (PCTU), Office of the Clinical Director, NIAMS, NIH, Bethesda, MD, ³Rehabilitation Medicine Department, Physical Therapy Section, Clinical Research Center, NIH, Bethesda, MD, ⁴Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ⁵Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ⁶Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Bethesda, MD
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…
Abstract Number: 847 • 2019 ACR/ARP Annual Meeting
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 7 Years: An Updated Integrated Safety Analysis
Mark Genovese¹, Josef Smolen ², Tsutomu Takeuchi ³, Gerd Burmester ⁴, Dennis Brinker ⁵, Terence Rooney ⁵, Jinglin Zhong ⁶, Daojun Mo ⁵, Chadi Saifan ⁵, Anabela Cardoso ⁵, Maher Issa ⁵, Wen-Shuo Wu ⁵ and Kevin Winthrop ⁷, ¹Stanford University, Stanford, CA, ²Medical University of Vienna, Vienna, Austria, ³Keio University School of Medicine, Tokyo, Japan, ⁴Charité—University Medicine Berlin, Berlin, Germany, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶IQVIA, Morrisville, NC, ⁷Oregon Health and Science University, Portland, OR
Background/Purpose: Baricitinib (bari), an oral, selective inhibitor of Janus kinase (JAK) 1 and 2, is used to treat moderately to severely active RA in adults.…
Abstract Number: 1039 • 2019 ACR/ARP Annual Meeting
Molecular Profiling Identifies Immunologic Subgroups and Informs Mechanism of Action of Baricitinib in SLE
Thomas Dörner¹, Yoshiya Tanaka ², Michelle Petri ³, Josef Smolen ⁴, Daniel Wallace ⁵, Ernst Dow ⁶, Damiano Fantini ⁶, Richard Higgs ⁶, Guilherme Rocha ⁶, Brenda Crowe ⁶, Robert Benschop ⁶, Adam Abel ⁶, Nicole Byers ⁶, Maria Silk ⁶, Stephanie de Bono ⁶ and Robert Hoffman ⁶, ¹Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Medical University of Vienna, Vienna, Austria, ⁵Cedars-Sinai Medical Center/University California at Los Angeles, Los Angeles, CA, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib is an oral selective Janus kinase (JAK) 1 and JAK2 inhibitor. In the Phase II, 24-week, randomized, placebo-controlled, double-blind study JAHH (NCT02708095), once-daily…
Abstract Number: 1350 • 2019 ACR/ARP Annual Meeting
Patient Disease Trajectories in Baricitinib-2 Mg-Treated Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs
Mark Genovese¹, Michael Weinblatt ², Jianmin Wu ³, Bochao Jia ³, Amanda Quebe ³, Luna Sun ³, Yun-Fei Chen ³, Cameron Helt ³, A. Kirstin Bacani ³, Paulo Reis ³ and Janet Pope ⁴, ¹Stanford University, Stanford, CA, ²Brigham and Women's Hospital, Boston, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Western University, London, ON, Canada
Background/Purpose: Baricitinib (BARI), a selective Janus kinase 1 and 2 inhibitor, is approved for the treatment of moderately-to-severely active RA in over 60 countries. In…
Abstract Number: 1407 • 2019 ACR/ARP Annual Meeting
Baricitinib Provides Better Pain Relief Across All Disease Activity Levels Compared with Placebo and Adalimumab in Rheumatoid Arthritis
Peter Taylor¹, Janet Pope ², Kei Ikeda ³, Xiang Zhang ⁴, Bochao Jia ⁴, Hong Zhang ⁵, Amanda Quebe ⁴, Yun-Fei Chen ⁴, Carol Gaich ⁴, Thorsten Holzkaemper ⁴, Anabela Cardoso ⁴ and Anthony Sebba ⁶, ¹University of Oxford, Oxford, United Kingdom, ²Western University, London, ON, Canada, ³Chiba University Hospital, Chiba, Japan, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵TechData Services, King of Prussia, PA, ⁶University of South Florida, Palm Harbor, FL
Background/Purpose: In Phase 3 trial, RA-BEAM, baricitinib (BARI), a JAK1/JAK2 inhibitor, was associated with significant clinical improvements vs. placebo (PBO) and adalimumab (ADA) in RA…
Abstract Number: 1439 • 2019 ACR/ARP Annual Meeting
Effect of Baricitinib on Functional Impairment in RA Patients with Moderate Disease Activity and an Inadequate Response to Conventional DMARDs
Bruce Kirkham¹, Elena Nikiphorou ², Pedro López-Romero ³, Ilias Kouris ³, Thorsten Holzkaemper ³, Liliana Zaremba-Pechmann ⁴, Inmaculada de la Torre ³ and Peter Taylor ⁵, ¹Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ²King's College London, London, United Kingdom, ³Eli Lilly and Company, Indianapolis, IN, ⁴HaaPACS GmbH, Schriesheim, Germany, ⁵University of Oxford, Oxford, United Kingdom
Background/Purpose: In RA, disease activity correlates with physical function1 and there is a link between joint damage and functional disability2. In many countries, RA patients…
Abstract Number: 1772 • 2019 ACR/ARP Annual Meeting
Chronotherapy Using Baricitinib Attenuates Collagen-induced Arthritis in Mice
Arisa Yaekura¹, Kanta Morii ², Yuto Oketani ³, Ikumi Okumura ², Kenta Kaneshiro ⁴, Kohsuke Yoshida ², Yoshiko Kawasaki ⁵, Nao Shibanuma ⁵, Yoshitada Sakai ⁶ and Akira Hashiramoto ², ¹Kobe University Graduate School of Health Sciences, Kawanishi, Hyogo, Japan, ²Kobe University Graduate School of Health Sciences, Kobe, Hyogo, Japan, ³Kobe University Graduate School of Health Sciences, Himeji, Hyogo, Japan, ⁴Kobe University Graduate School of Health Sciences, Osaka, Osaka, Japan, ⁵Kobe Kaisei Hospital, Kobe, Hyogo, Japan, ⁶Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
Background/Purpose: Diurnal variations are observed in symptoms of rheumatoid arthritis (RA). Among them, “morning stiffness of joints” is closely reflects the daily medical condition of…

Efficacy of Long-term Treatment with Baricitinib 2 Mg in Patients with Active Rheumatoid Arthritis

Monitoring of BK Reactivation and Long-term Safety on JAK1/2 Inhibition with Baricitinib

Delineation of a Proinflammatory Cytokine Profile Targeted by Janus Kinase 1/2 Inhibition Using Baricitinib in a Phase 2 Systemic Lupus Erythematosus Trial

Baricitinib 2-mg Provides Greater Improvements in Patient-Reported Outcomes Across All Disease Activity Levels Compared to Placebo: Post-hoc Analyses of RA-BEACON and RA-BUILD Trials

Radiographic Progression of Structural Joint Damage over 5 Years of Baricitinib Treatment in Patients with Rheumatoid Arthritis: Results from RA-BEYOND

Cinematic Rendering Enables Depiction of Bone Anabolic Effects in Patients Treated with Baricitinib

Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis

Screening and Treating Hyperlipidemia in Patient’s on Tofacitinib, Tocilizumab, Sarilumab, and Baricitinib

Preliminary Response to Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis

Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 7 Years: An Updated Integrated Safety Analysis

Molecular Profiling Identifies Immunologic Subgroups and Informs Mechanism of Action of Baricitinib in SLE

Patient Disease Trajectories in Baricitinib-2 Mg-Treated Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs

Baricitinib Provides Better Pain Relief Across All Disease Activity Levels Compared with Placebo and Adalimumab in Rheumatoid Arthritis

Effect of Baricitinib on Functional Impairment in RA Patients with Moderate Disease Activity and an Inadequate Response to Conventional DMARDs

Chronotherapy Using Baricitinib Attenuates Collagen-induced Arthritis in Mice

Simple Search Results